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Abstract
Objective: Atherosclerosis is a chronic inflammatory disorder that involves a range of inflammatory mediators. Although
interleukin (IL)-9 has been related to inflammation, there are at present no data on its role in atherosclerosis. Here we have
examined IL-9 and IL-9 receptor (IL-9R) systemically and locally in patients with coronary and carotid atherosclerosis.
Methods: Plasma IL-9 was quantified by enzyme immunoassay and multiplex technology. IL-9 and IL-9R mRNA were
quantified by real-time RT-PCR, and their localization within the lesion was assessed by immunohistochemistry.
Results: The main findings were: (i) Patients with carotid atherosclerosis had significantly raised IL-9 plasma levels compared
with healthy controls (n = 28), with no differences between asymptomatic (n = 56) and symptomatic (n = 88) patients. (ii) On
admission, patients with acute ST-elevation myocardial infarction (STEMI) (n = 42) had markedly raised IL-9 plasma levels
which gradually declined during the first week post-MI. (iii) T cells and monocytes from patients with unstable angina
(n = 17) had increased mRNA levels of IL-9 as compared with controls (n = 11). (iv) Carotid plaques (n = 68) showed increased
mRNA levels of IL-9 and IL-9R compared to non-atherosclerotic vessels (n = 10). Co-localization to T cells (IL-9 and IL-9R) and
macrophages (IL-9) were shown by immunohistochemistry. (v) IL-9 increased IL-17 release in peripheral blood mononuclear
cells from patients with unstable angina (n = 5) and healthy controls (n = 5) with a particularly enhancing effect in cells from
the patient group.
Conclusion: Our findings show increased IL-9 levels in different atherosclerotic disorders both systemically and within the
lesion, suggesting a role for the IL-9/IL-9R axis in the atherosclerotic process, potentially involving IL-17 mediated
mechanisms. However, the functional consequences of these findings should be further investigated.
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Introduction
Complications from atherosclerosis are the leading causes of
death in the Western world. Atherosclerotic plaque development is
now regarded as a chronic inflammatory process which involves
interactions between lipids, immune cells and the artery wall [1].
The inflammatory arm of atherosclerosis involves both adaptive
and innate immune responses, and may be a common link for
many atherosclerotic risk factors (e.g., obesity, hyperlipidemia and
smoking) [2]. The small cell-regulatory proteins, called cytokines,
are key players in this inflammatory network. Several studies
demonstrate altered levels of various cytokines in atherosclerotic
disorders, both systemically and within the atherosclerotic plaque
[3]. However, although the concept of inflammation as a major
mediator in atherosclerosis is well established, the identification of
the different actors in this complex network is not fulfilled.
Interleukin (IL)-9 was first recognized as a T helper cell type 2
(Th2)-related cytokine, but it is now clear that IL-9 is produced by
various CD4+ T-cell subsets, including the newly defined Th9 cells
[4]. IL-9 expression is also observed in granulocytes, dendritic cells
and mast cells [5–8]. The IL-9 receptor (IL-9R) consists of a
specific a-chain and a signal unit (c-chain) that is shared with other
members of the IL-2-related cytokine family such as IL-2, IL-4,
IL-7 and IL-15. While IL-9 has been implicated as a pathogenic
mediator of asthma and allergic disorders, recent studies suggest
that IL-9 may enhance as well as dampen the progression of
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various autoimmune disorders [9–12]. Increased plasma levels of
IL-9 are seen in patients with heart failure, possibly correlated to
disease progression [13], and increased IL-9 levels have been
reported in experimental cardiomyopathy [14]. IL-9 has also been
shown to facilitate Th17 cell expansion, and to stimulate
production of IL-17 from mononuclear cells of both healthy and
diseased subjects such as patients with psoriasis [15]. To this end,
however, there are to the best of our knowledge, no data on the
regulation of IL-9 in atherosclerotic disorders.
Based on its known association with other inflammatory
conditions, we hypothesized that IL-9 could be involved in the
inflammatory arm of atherosclerotic disease. We examined this
hypothesis by various experimental approaches including studies
on the expression of IL-9 and IL-9R in patients with carotid and
coronary atherosclerosis. We also assessed the ability of IL-9 to




The study protocols were approved by the Regional Health
Authorities of South-Eastern and Western Norway. The study
confirms with the principles outlined in the Declaration of Helsinki
for use of human tissue or subjects. Signed informed consent was
obtained from all participants.
Patients and Control Subjects
Three populations of patients with atherosclerotic disorders
were investigated. (i) Patients with carotid atherosclerosis. Patients
(n = 144) with high-grade internal carotid stenosis ($70%) treated
with endarterectomy or carotid angioplasty with stenting were
included in the study (Table S1). The patients were classified as
asymptomatic (n = 56) or symptomatic (n = 88) in accordance to
absence or presence of clinical symptoms (i.e., stroke, transient
ischemic attack (TIA) or amaurosis fugax ipsilateral to the stenotic
internal carotid artery within the past 6 months). Carotid stenoses
were diagnosed and classified by precerebral color Duplex
ultrasound and CT angiography according to consensus criteria
[16,17]. The asymptomatic carotid stenoses were detected during
clinical examinations of patients with coronary artery disease
(CAD), peripheral artery disease or stroke/TIA more than 6
months previously. For comparison, plasma was collected from 28
sex- and age-matched healthy subjects (Table S1). (ii) Patients with
ST segment elevation myocardial infarction (STEMI). Plasma samples
from 42 patients with first time STEMI were obtained at
admission, immediately prior to percutaneous coronary interven-
tion (PCI) and 2, 7 and 60 days following hospitalization (Table
S2). Median time from symptom debut to admission was 145
minutes (range: 25–720 minutes). The study design has previously
been described [18] and patients were included if they had (i) no
previous MI, (ii) demonstrated acute proximal/mid-occluded
single vessel disease and (iii) underwent successful PCI with stent
implantation without significant residual stenosis. For comparison,
plasma was collected from 10 sex- and age-matched healthy
subjects. (iii) Patients with stable and unstable angina. IL-9 and IL-9R
mRNA expression were examined in T cells and monocytes from
30 CAD patients and 11 sex- and age-matched healthy subjects.
The patient population consisted of 13 patients with stable and 17
patients with unstable angina. Patients with unstable angina were
characterized by chest pains at rest within the preceding 48 hours
with transient ST-T segment depression and/or T-wave inversion
(i.e., Braunwald’s class IIIBa), but with no evidence of myocardial
necrosis by enzymatic criteria. Patients with stable CAD showed
stable effort angina with over 6 month duration and a positive
exercise test. All patients had angiographically documented
obstruction ($50%) of at least one main coronary artery.
Exclusion criteria were MI or thrombolytic therapy in the
previous month.
In all sub-studies, patients with contaminant inflammatory
diseases, malignancies or overt liver and kidney disease were
excluded.
Blood Sampling Protocol
Blood samples from all patients and controls were drawn into
pyrogen-free EDTA tubes, immediately placed on ice, and
centrifuged at 2500g for 25 minutes within 20 minutes to obtain
platelet-poor plasma. Plasma was stored at 280uC until analyses.
Samples were thawed less than three times.
Tissue Sampling from Carotid Plaque
Atherosclerotic carotid plaques were collected during carotid
endarterectomy. Plaques that were used for RNA extraction were
rapidly frozen in liquid nitrogen. Plaques that were used for
immunohistochemistry (IHC) were placed in 4% phosphate
buffered-formalin for 48 hours and then embedded in paraffin.
For mRNA analyses samples from the common iliac artery of
deceased organ donors were used as non-atherosclerotic vessel
controls. Control tissues were prepared and stored in the same way
as carotid plaques.
Isolation of Leukocyte Subsets
Peripheral blood mononuclear cells (PBMCs) were separated
from heparinized blood by Isopaque-Ficoll gradient centrifugation
using Lymphoprep (Nycomed, Oslo, Norway). PBMCs were
immediately used for in vitro experiments or for further separation
of CD14+ monocytes (CD14-labeled magnetic beads; MACS,
Milteny Biotec, Bergisch Gladbach, Germany) and CD3+ T-cells
(negative selection by monodisperse immunomagnetic beads;
Dynal, Oslo, Norway) as described elsewhere [19,20]. After
isolation, the cells were immediately stored in liquid nitrogen. The
selected T cells consisted of .90% CD3+ cells and the isolated
monocytes of .95% CD14+ cells as assessed by flow cytometry.
Immunohistochemistry
Sections (5 mm) of paraffin-embedded atherosclerotic vessels
were treated with 0.5% H202, followed by high-temperature
Figure 1. Increased plasma levels of IL-9 in patients with
carotid and coronary atherosclerosis. Panel A shows plasma levels
of IL-9 in patients with asymptomatic (n = 56) and symptomatic (n = 88)
carotid plaques and in healthy controls (n = 28). Panel B shows plasma
levels of IL-9 in patients with STEMI (n = 42) at admission and at
different time points after PCI (2, 7 and 60 days). For comparison, levels
were also measured in healthy controls (n = 10). Data are presented as
mean6SEM. *p,0.05, **p,0.01 and ***p,0.0001 versus controls.
#p,0.05 and ##p,0.01 versus levels at admission.
doi:10.1371/journal.pone.0072769.g001
Increased Interleukin 9 Levels in Atherosclerosis
PLOS ONE | www.plosone.org 2 August 2013 | Volume 8 | Issue 8 | e72769
unmasking in citrate-buffer (pH 6.0), blocked with 0.5% bovine
serum albumin (BSA) and then incubated with primary antibodies
(anti-IL-9; Santa Cruz Biotechnology, CA and anti-IL-9R;
Abcam, Cambridge, UK) for one hour at room temperature.
After washing, the slides were incubated for an additional 30
minutes with peroxidase-conjugated secondary antibodies (Im-
press-Vector, Vector laboratories, Burlingame, CA), rinsed and
developed with chromogen for immunoperoxidase staining (DAB
Plus, Vector laboratories) for seven minutes. The sections were
counterstained with Hematoxylin. Omission of the primary
antibody served as a negative control.
Immunofluorescence
Paraffin-embedded sections (5 mm) of atherosclerotic carotid
plaques were exposed to high-temperature unmasking (citrate-
buffer, pH 6.0), blocked in 0.5% BSA and incubated over night at
4uC with primary antibodies (anti-IL-9; Santa Cruz Biotechnol-
ogy, CA, anti-IL-9R; Abcam, Cambridge, UK, anti-CD68;
DAKO, Glostrup, Denmark and anti-CD3; Santa Cruz Biotech-
nology). The sections were counterstained with secondary
antibodies, Alexa Fluor 488 and 568 (both from Invitrogen,
Eugene, OR). Nuclei were stained with diamidino-2-phenylindole
(DAPI) (Slow Fade Gold antifade reagent, Invitrogen). Fluorescent
images were obtained on a Nikon Eclipse E400 microscope with
4006magnification.
Cell Culture Experiments
Freshly isolated PBMCs were incubated in flat-bottomed 24-
well microtitre plates (26106/ml, 500 ml/well; Costar, Sigma-
Aldrich, St. Louis, MO) with RPMI 1640 medium (PAA
Laboratories, Pasching, Austria) supplemented with 10% heat
inactivated human AB+ serum (Invitrogen, Carlsbad, CA) and
1% Penicillin-Streptomycin (Sigma). The cells were stimulated
with recombinant human IL-9 (100 ng/ml, R&D Systems,
Minneapolis, MN) with and without phytohaemagglutinin
(PHA, 20 mg/ml; Thermo Scientific, Waltham, MA). Cell-free
supernatants were harvested after 24, 48 and 72 hours and
stored at 280uC.
Measurements of Cytokines
In patients with carotid atherosclerosis and corresponding
controls, plasma levels of IL-9 was quantified by enzyme
immunoassay (EIA) obtained from eBioscience (San Diego, CA).
In STEMI patients and corresponding controls, plasma levels of
IL-9 was quantified by multiplex cytokine immunoassay (Bio-Plex,
Bio-Rad Laboratories, Hercules, CA), analyzed on a Multiplex
Analyzer (Bio-Rad Laboratories). In the in vitro-experiments, IL-
17AF, hereafter termed IL-17, was analyzed in supernatants by
EIA (R&D Systems).
Real-time Quantitative RT-PCR
Total RNA was obtained from atherosclerotic and non-
atherosclerotic vessels and from T cell and monocytes with the
use of RNeasy spin columns (QIAGEN, Hilden, Germany). All
samples were subjected to DNase treatment (RQI DNase;
Promega, Madison, WI) and stored at 280uC until further
analysis. cDNA synthesis was performed using the High-Capacity
cDNA Reverse Transcriptation Kit (Applied Biosystems, Foster
City, CA). Gene expression was examined by real-time quantita-
tive RT-PCR (7500 Fast Real-Time PCR System, Applied
Biosystems). Sequence specific TaqMan primers and probes were
used for IL-9R detection (Assay-ID: HS_00602538_M1, Applied
Biosystems). mRNA detection of IL-9 and the reference genes b-
actin and 18S RNA were assessed with SyberGreen primers
designed using Primer Express software 3.0 (Applied Biosystems):
(IL-9: forward primer [FP] 59-AGTGCAGTGGTGC-
CATCTGA-39 and reverse primer [RP]: 59-ACGCACCTG-
TAATGCCAGCTA-39), b-actin: (FP 59-AGGCAC-
CAGGGCGTGAT-39 and RP 59-
TCGTCCCAGTTGGTGACGAT-39) and 18S (FP 59-
Figure 2. Increased expression of IL-9 and IL-9R in immune cells from patients with coronary atherosclerosis. mRNA levels of IL-9 and
IL-9R were quantified by real-time RT-PCR in CD3+ T cells (A and B) and in monocytes (C) from healthy controls (n = 11) and from patients with stable
(SAP, n = 11) and unstable (UAP, n = 17) angina. mRNA levels are related to the reference gene 18S (T cells) and b-actin (monocytes) and normalized to
levels in healthy controls. For monocyte analyses, only samples from 9 of the controls and 13 of the patients with unstable angina were available. No
IL-9R transcripts were detected in patients or controls in these cells. Bars represent mean6SEM. #p,0.05 versus stable angina, *p,0.05 and
**p,0.01 versus controls.
doi:10.1371/journal.pone.0072769.g002
Figure 3. Increased expression of IL-9 and IL-9R in human
atherosclerotic carotid plaques. mRNA levels of IL-9 (A) and IL-9R
(B) in patients with asymptomatic (n = 13) and symptomatic (n = 55)
carotid stenosis and in non-atherosclerotic vessels obtained from organ
donors (common iliac artery, n = 10) were quantified by real-time RT-
PCR. No IL-9R transcripts were detected in control samples. Levels of IL-
9 and IL-9R expression are related to reference gene b-actin. Data are
presented as mean6SEM. ***p,0.0001 versus controls.
doi:10.1371/journal.pone.0072769.g003
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CGGCTACCACATCCAAGGAA-39 and RP 59-GCTGGAAT-
TACCGCGGCT-39). The relative mRNA level of each transcript
was calculated by the DDCt-method.
Statistical Analysis
For unpaired data the Mann-Whitney U-test and Kruskal-
Wallis test were used when appropriate. For paired data the
paired t-test or Wilcoxon signed rank test was used. The chi-
square and Fischer’s exact test were used for categorical data.
Statistical significance was considered at p,0.05 for all data.
Results
Increased Circulating Levels of IL-9 in Carotid
Atherosclerosis
Baseline characteristics of the patients with carotid atheroscle-
rosis are shown in Table S1. Both asymptomatic and symptomatic
patients had significantly higher plasma levels of IL-9 than healthy
controls, with no significant difference between the two patient
groups (Fig. 1A). In the patient group as a whole, we found no
significant correlation between IL-9 levels and any of the variables
outlined in Table S1.
Figure 4. Localization of IL-9 in human carotid atherosclerotic plaques. Panel A shows immunostaining of IL-9 and IL-9R in symptomatic
carotid atherosclerotic plaques. Representative images obtained with 1006and 4006objective. Omission of primary antibody is shown as a negative
control. Panel B shows double immunofluorescent staining of IL-9 (red fluorescence), CD68 (macrophages, green fluorescence) and nucleus (DAPI,
blue fluorescence) from symptomatic carotid atherosclerotic plaques. The bottom right picture is a merge of the three. Panel C shows staining of IL-9
(red) and CD3 (T-cells, green), nucleus (blue) and merge. Panel D shows staining of IL-9R (red) and CD3 (T-cells, green), nucleus (blue) and merge. The
pictures are representatives of multiple staining (n = 5–8).
doi:10.1371/journal.pone.0072769.g004
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Increased Circulating Levels of IL-9 in Coronary
Atherosclerosis
We next examined circulating IL-9 levels in a STEMI
population, representing another atherosclerotic disorder (Table
S2). Plasma IL-9 was significantly elevated in these patients at
admission compared to healthy controls (Fig. 1B). From 48 hours
following PCI, there was a gradual decline in IL-9, almost
reaching normal levels during the end of the observation period
(Day 60). Prior to PCI no correlation between IL-9 and CRP or
maximum troponin T was observed for these patients.
Increased Expression of IL-9 and IL-9R in CD3+ T cells and
CD14+ Monocytes in Patients with Coronary
Atherosclerosis
To further examine the regulation of IL-9 in atherosclerotic
disorders, we analyzed mRNA levels of IL-9 and IL-9R in T cells
and monocytes from patients with stable and unstable angina and
in healthy controls. T cells from patients with unstable, but not
stable angina had significantly increased mRNA expression of IL-9
and IL-9R compared with T cells from healthy controls, and for
IL-9, the difference between unstable and stable disease was also
significant (Fig. 2A–B). The same pattern was seen for IL-9 in
monocytes with increased mRNA levels in unstable, but not in
patients with stable angina compared to healthy controls (Fig. 2C).
IL-9R transcripts were not detected in monocytes from patients or
controls.
Increased Expression of IL-9 and IL-9R in Atherosclerotic
Carotid Plaques
The findings so far suggested increased systemic expression of
IL-9 in both carotid and coronary atherosclerosis. We therefore
examined whether increased IL-9/IL-9R levels could be found
within the atherosclerotic lesion. Carotid lesion samples from
patients with asymptomatic and symptomatic carotid atheroscle-
rosis had markedly increased expression of IL-9 and IL-9R as
compared with samples from non-atherosclerotic vessels (common
iliac artery, Fig. 3). In fact, while IL-9 mRNA was expressed in
both controls and patients, transcript of IL-9R could not be
detected in control samples (Fig. 3B). There were, however, no
differences between the two patient groups for either IL-9 or IL-
9R. Moreover, although markedly raised as compared with non-
atherosclerotic vessels, the transcript levels of IL-9 and IL-9R
within the lesion were in general low. Immunostaining confirmed
the expression of IL-9 and IL-9R within the plaque, and co-
localization with T cells (IL-9, IL-9R) and macrophages (IL-9) was
supported by co-staining to the respective cell markers, CD3 and
CD68 (Fig. 4).
IL-9 Promotes IL-17 Release from PBMCs
IL-9 has previously been reported to alter production of both
pro- and anti-inflammatory mediators in leukocyte subsets with
promotion of Th17 cells as one of its features [15,21–23]. To
examine any potential consequences of the increased IL-9 levels in
atherosclerotic disorders, we therefore next examined the effects of
IL-9 (100 ng/ml) on IL-17 release in PBMCs from patients with
unstable angina (n = 5) and healthy controls (n = 5), with and
without co-stimulation with PHA (20 mg/ml). IL-9 induced a
significant increase in IL-17 release in PHA activated PBMCs after
culturing for 72 hours in both patients and controls, with a
particularly enhancing effect in the patient group (Fig. 5). While
IL-9 when given alone induced a significant decrease of IL-17 in
PBMCs from healthy controls, there was a modest increase in IL-
17 from patient cells, resulting in a significant difference in
percentage change in the IL-9-induced IL-17 release between
patients and controls (Fig. 5A–B).
Discussion
Here we report for the first time increased levels of both IL-9
and IL-9R in patients with carotid and coronary atherosclerosis.
Through investigation of three different populations of athero-
sclerotic patients we found elevated circulating levels of IL-9 and
increased expression in cells and tissue of IL-9 and IL-9R,
compared to healthy controls.
IL-9 has previously been associated with inflammatory diseases
in several studies, especially in relation to allergies and asthma.
There are also some reports of increased IL-9 levels in relation to
systemic sclerosis and experimental transplant allograft rejection
[10–12,24]. However, the role of IL-9 in cardiovascular disorders
is largely unknown. Increased plasma IL-9 has been reported in
patients with ischemic and non-ischemic cardiomyopathies,
inversely correlated with parameters of impaired left ventricular
function [13], and increased serum IL-9 has also been reported in
45 patients with acute ischemic stroke of different etiology [25].
However, the present study is, to the best of our knowledge, the
first report of increased levels of IL-9 in patients with confirmed
coronary and carotid atherosclerosis. We found increased plasma
levels of IL-9 in patients with carotid atherosclerosis with no
differences between asymptomatic and symptomatic patients.
Moreover, patients with STEMI had markedly elevated IL-9
levels on admission, a few hours after symptom debut, with a
Figure 5. IL-9 promotes IL-17 release in PBMCs. PBMCs from
healthy controls (Ctr, n = 5) and patients with unstable angina (UAP,
n = 5) were stimulated with IL-9 (100 ng/ml) with and without co-
stimulation with PHA (20 mg/ml). Panel A shows the absolute release of
IL-17 after culturing for 72 hours as assessed by EIA measurements in
cell-free supernatants (controls to the left, patients to the right). Panel B
shows the percentage change in IL-17 release when adding IL-9 to
unstimulated cells from healthy controls (left) and patients (right). Panel
C shows the percentage change in IL-17 release when adding IL-9 to
PHA-stimulated cells from healthy controls (left) and patients (right).
Data are given as mean6SEM. *p,0.05 versus comparative condition
without IL-9 (unstimulated and PHA stimulated, respectively). #p,0.05
versus healthy controls.
doi:10.1371/journal.pone.0072769.g005
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gradual decline during the following week. In contrast to several
other inflammatory markers [18,26,27], there was no IL-9
increase following PCI, suggesting only minor regulation by
ischemia and reperfusion injury. Finally, enhanced expression was
also seen at the cellular level with increased levels of IL-9 mRNA
and IL-9R in T cells from patients with unstable angina, and for
IL-9, this up-regulation was also seen in monocytes.
In addition to increased systemic expression, the present study
also showed enhanced expression of IL-9 and its receptor within
the atherosclerotic lesion. Thus, when compared with non-
atherosclerotic vessels (common iliac artery), carotid plaques had
markedly elevated mRNA levels of IL-9 and IL-9R. Moreover IL-
9 co-localized to both T cells and macrophages and IL-9R to T-
cells, as assessed by IHC. The fact that IL-9 and IL-9R showed the
same pattern in asymptomatic and symptomatic lesions could
suggest that these mediators are related to the chronic atheroscle-
rotic process, rather than to plaque destabilization.
IL-9 has been shown to induce cytokine release from activated
mast cells, and IL-9 is also suggested to function as an autocrine
growth factor that facilitates the expansion of inflammatory Th17
cells [10,22,28]. Indeed, in the present study we found that IL-9
promoted a IL-17 release in PBMCs, with a particularly marked
response in cells from unstable angina patients. In fact, while IL-9
seemed to suppress IL-17 release in PBMCs from healthy controls,
it enhanced IL-17 release in cells from unstable angina patients.
These new findings further underscore a link between IL-9 and IL-
17 and suggest that this link is particularly strong in patients with
unstable angina, potentially reflecting up-regulation of IL-9R in T
cells from these patients. However, IL-9 may also possess anti-
inflammatory properties by enhancing the function of regulatory T
cells [22] and by suppressing IL-12 production in certain antigen
presenting cells [29]. Moreover, of relevance to stroke, IL-9 has
been shown to protect cortical neuron from cell death by anti-
apoptotic mechanisms [30], and further studies are clearly needed
to elucidate the net effect of IL-9 levels in atherosclerotic disorders.
In this study we demonstrate increased levels of IL-9, as well as
increased expression of IL-9R, both systemically and within the
lesion of patients with atherosclerotic disorders. This suggests a
role for the IL-9/IL-9R interaction in atherosclerosis, but the
functional consequences of these findings are at present unclear.
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